Legal Settlements and Loss Contingencies	9 Months Ended
Sep. 30, 2023
Legal Settlements and Loss Contingencies	NOTE 9 – Legal settlements and loss contingencies: In the third quarter of 2023, Teva recorded expenses of $314 million in legal settlements and loss contingencies, compared to $195 million in the third quarter of 2022. Expenses in the third quarter of 2023 were mainly related to an update to the provision for the DOJ patient assistance program litigation, as well as an update to the estimated settlement provision of the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). Expenses in the third quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, and an estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the U.S in the generic drug antitrust litigation. See note 10. In the first nine months of 2023, Teva recorded expenses of $1,009 million in legal settlements and loss contingencies, co m pared to $2,048 million in the first nine months of 2022. Expenses in the first nine months of 2023 were mainly related to an estimated provision for the DOJ patient assistance program litigation, an update to the estimated settlement provision of the opioid cases, the provision for the settlement of the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products and the provision for the settlement of the reverse-payment antitrust litigation over certain HIV medicines. Expenses in the first nine months of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases. As of September 30, 2023 and December 31, 2022, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,905 million and $4,186 million, respectively.

Legal Settlements and Loss Contingencies

9 Months Ended

Sep. 30, 2023

Legal Settlements and Loss Contingencies

NOTE 9 – Legal settlements and loss contingencies:

In the third quarter of 2023, Teva recorded expenses of $314 million in legal settlements and loss contingencies, compared to $195

million in the third quarter of 2022. Expenses in the third quarter of 2023 were mainly related to an update to the provision for the DOJ patient assistance program litigation, as well as an update to the estimated settlement provision of the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). Expenses in the third quarter of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases, and an estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the U.S in the generic drug antitrust litigation. See note 10.

In the first nine months of 2023, Teva recorded expenses of $1,009 million in legal settlements and loss contingencies, co

pared to $2,048

million in the first nine months of 2022. Expenses in the first nine months of 2023 were mainly related to an estimated provision for the DOJ patient assistance program litigation, an update to the estimated settlement provision of the opioid cases, the provision for the settlement of the U.S. DOJ criminal antitrust charges on the marketing and pricing of certain Teva USA generic products and the provision for the settlement of the reverse-payment antitrust litigation over certain HIV medicines. Expenses in the first nine months of 2022 were mainly related to an update of the estimated settlement provision recorded in connection with the remaining opioid cases.

As of September 30, 2023 and December 31, 2022, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,905 million and $4,186 million, respectively.